Kineticos Ventures

About Kineticos Ventures

Kineticos Ventures’ portfolio of investments is made up of biotechs striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated. The Kineticos Ventures fund focuses on significant, unmet medical needs in antimicrobial resistance (AMR), oncology, neurosciences, and rare diseases.

Kineticos will support early-stage AMR businesses with founders who have created unique, innovative, and know-how-protected products and services. We seek companies focused on therapeutics, diagnostics, and novel anti-microbial and anti-fungal technologies.

In addition to targeting these disease states with patients in need, we look for biotechs utilizing disruptive technologies such as cell and gene therapy, gene editing, and mRNA/RNAi, all technologies dramatically changing how medicine is practiced.

To learn more about Kineticos Ventures, you can reach us at investorrelations@kineticos.com

Funding Coupled with Execution Build Lasting Biotechs

While financial resources are essential for the growth of emerging biotechs, the addition of in-depth industry knowledge, industry relationships, a community of advisors, and thoughtful execution are critical for these young companies to succeed.

Kineticos Ventures forms comprehensive relationships and is thoroughly involved in the effort to help companies grow and develop—early funding is just the beginning.

Kineticos Ventures Criteria

We seek portfolio companies possessing characteristics critical for success

Team

Team

The ability to recruit best-in-class scientists and entrepreneurial business leaders

Platform Technology

Platform Technology

Disruptive technologies with high potential ROI

Medical Need

Medical Need

Unmet needs in AMR, oncology, neurosciences, and rare diseases

Protected IP

Protected IP

Ample intellectual property protections for platform technologies

Commercial Potential

Commercial Potential

Viable, accessible commercial market with ample reimbursement

Regulatory Path

Regulatory Path

Clear regulatory path for pre-clinical, clinical, and CMC development